



# Exploration of access and benefit sharing models: The common domain model.

Marcel Jaspars

Director, Marine Biodiscovery Centre; Leader PharmaSea Consortium


University of Aberdeen, Scotland, UK

[m.jaspars@abdn.ac.uk](mailto:m.jaspars@abdn.ac.uk)

With thanks to Thomas Vanagt, Arianna Brogiato, Harriet Harden-Davies & Hiroko Muraki Gottlieb





# Biodiscovery from BBNJ




Sampling in ABNJ



MGR



Chemistry



Bioassay



Product



Elements of good practice already exist at all stages of the marine biodiscovery pipeline






# Benefit Sharing

- Must be multilateral compared to bilateral for Nagoya Protocol
- In most cases most important benefits from use of MGR are non-monetary.
- Non-monetary benefits may include:
  - Scientific exchanges/training
  - Technology transfer
  - Capacity building (infrastructure)
  - Enhanced reputation
  - Increased number/quality of scientific publications
  - Biodiversity conservation
  - Valuable regional resources developed (knowledge, samples, data)
- Non-monetary benefits still cost money – however they are upfront compared to royalties

# Benefit Sharing

- Multilateral NOT Bilateral
- Most important benefits are non-monetary.


## Public domain approach



Biobricks



open source™



- Low cost
- Benefits will accrue where MGR are used
- All should be able to benefit from research, development and commercialisation on MGR from ABNJ
- Requires capacity building to ensure fairness
- This approach will lead to greater innovation, transparency and openness

## IUCN Matrix: Public Domain

- Create a multilateral/pool system based on the public domain approach facilitating international access to and scientific research on MGR from ABNJ as well as associated raw data
- Fair and equitable sharing of non-monetary benefits, in particular by putting samples of MGR collected in ABNJ as well as associated data in the public domain as soon as possible (use embargo period)
- Share further non-monetary benefits by facilitating international collaboration, technology transfer and capacity-building
- Fair and equitable sharing of monetary benefits in case of commercialisation

# The Idea



```

MQPTALQIKPHFHVVEIEPKQVYLLGEGQNHALTGQLY
LSRLVEKGYLTVAPELSLEVAWFSELGIAPSVVAEG
VSDPKAPKAPKAGDSTAQLQVVLTDDYLQPELAAINKE
HCLAQRLLRGNREVEASVLQKRALQERNQONKNGAVSC
NAIA
RATT
DSQS
PHRF
RDSV
IGFG
RWSD
PLAE
MQSTTLQIKPHFHVVEIEPKQVYLLGEGQNHALTG
VLNRLAEKGYLTEATPDLSPVAAPFTELGIAPTVA
PVQNASDIGSSAALNIVLTDYLLQPELAAINKQALQ
RLRGNREMQSTPLLQIQPHFHVVEIEPKQVYLLGEGQANY
TALFPTLVLDRLAEKGYLTAAPELSSEVAAPFSELGIA
QTLQKYQVQVTSFEAGSPALNVVLTDDYLQPELAKINKQ
GFCEAVEILRGNREVEASVLQKQQAQQQRNGQSGSVISCL
QAIDWTFVFFPTLDGKIITFNHTVIDLKSHVLRVPQCP
WYNRLSRITVQKYQHLSVPTIGVVTELVRITDPANPLVHT
DPTIGILLCEAIERYSIGIFOGDEPWKRATLAEGLDALH
TDVMTCVIAIDWTFVNSLTEQKHXYVPTAFQYGYPLPEE
NPMNIPFYNRIRRPVAVDLSTFDEPFYVDLQQFYQQQNRRE
PTIAILRALTEVSVQVLELDKIIPDKLDGESK
DVMNCVKTAQTAGLEVNVLDQTRPDIIGLVVK
QTNIPF
    
```

MGR samples  
and raw data



Share samples and data




(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(19) World Intellectual Property Organization  
International Bureau

(43) International Publication Date  
13 September 2007 (13.09.2007)

(10) International Publication Number  
WO 2007/103739 A2



Commercialisation  
(not just IP filing  
but use of IP)




Basic  
research





# Commercialisation

Where is the transition from basic research to research with commercial intent? (when does actual value become apparent?)



# PHARMASEA



*“The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013 under grant agreement n ° 312184)”*